clinical trial · NCT07434050
A Study of XW003 in Obese Participants With Obstructive Sleep Apnea Receiving Positive Airway Pressure Therapy
Hangzhou Sciwind Biosciences Co., Ltd.·phase3·recruiting·n = 140
OSA - Obstructive Sleep ApneaObesityXW003 injectionplacebo with matching volume
brief summary
The aim of the study is to assess the efficacy and safety of XW003 injections in obese participants with OSA receiving PAP
started
Mar 2, 2026
primary completion
Jun 19, 2028
completion
Jun 19, 2028
last updated
Apr 13, 2026
detailed description
In this Phase III study, eligible participants will be randomized into one of the two cohorts in a 1:1 ratio to receive once-weekly subcutaneous XW003 injection or placebo, including a dose-escalation period, for up to 48 weeks
official title
A Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Study to Assess the Efficacy and Safety of XW003 Injections in Obese Participants With Obstructive Sleep Apnea Receiving Positive Airway Pressure Therapy
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol